Recherche
-
The radiologically isolated syndrome: revised diagnostic criteria
(Brain - A Journal of Neurology, 2023-03-02)Article de revue -
Serum Neurofilament Levels and PML Risk in Patients With Multiple Sclerosis Treated With Natalizumab
(Neurology. vol. 8, n° 4, 2021-04-26)Article de revueLibre accès -
Comparative Effectiveness of Natalizumab Versus Anti-CD20 in Highly Active Relapsing–Remitting Multiple Sclerosis After Fingolimod Withdrawal
(Neurotherapeutics. vol. 19, n° 2, pp. 476-490, 2022-03)Article de revueLibre accès -
Investigating the Long-term Effect of Pregnancy on the Course of Multiple Sclerosis Using Causal Inference.
(Neurology. vol. 100, n° 12, pp. e1296-e1308, 2023-03-21)Article de revueLibre accès -
Immune Profiling Reveals the T-Cell Effect of Ocrelizumab in Early Relapsing-Remitting Multiple Sclerosis
(Neurology(R) neuroimmunology & neuroinflammation. vol. 10, n° 3, 2023-02-21)Article de revueLibre accès -
Progressive Multifocal Leukoencephalopathy Incidence and Risk Stratification among Natalizumab Users in France
(JAMA Neurology. vol. 77, n° 1, pp. 94-102, 2020-01-01)Article de revueLibre accès -
Comparison of Simoa™ and Ella™ to assess serum neurofilament-light chain in multiple sclerosis
(Annals of Clinical and Translational Neurology. vol. 8, n° 5, pp. 1141-1150, 2021-05)Article de revueLibre accès -
Highly Effective Therapies as First-Line Treatment for Pediatric-Onset Multiple Sclerosis
(JAMA neurology. vol. 81, n° 3, pp. 273-282, 2024-03-01)Article de revueLibre accès